4/A: Clene CSO Stock Option Price Corrected in Amended Filing

Clene Inc.'s Chief Science Officer, Mark Mortenson, filed an amended Form 4 to correct the exercise price of 40,000 stock options to $5.88 per share.

Summary

• Mark Mortenson, Chief Science Officer of Clene Inc. (CLNN), filed an amended Form 4.
• The amendment corrects the exercise price of 40,000 stock options previously reported.
• The corrected exercise price for these options is $5.88 per share.
• The options were granted on September 25, 2025, under the Clene Inc. Amended 2020 Stock Plan.
• These options vest in 12 equal monthly installments, beginning October 25, 2025, until fully vested.
• The expiration date for these options is September 24, 2035.

Sentiment

Score: 5

Explanation: The filing is a neutral administrative correction of an exercise price for an existing stock option grant, with no new material financial or operational information.

Future Outlook

The stock options granted to the Chief Science Officer will vest in 12 equal monthly installments, commencing on October 25, 2025, indicating a future schedule for equity compensation realization.

Industry Context

This filing is an insider transaction amendment, which is a routine disclosure for publicly traded companies regarding executive equity compensation. It does not provide information directly related to broader industry trends or competitive landscape.

Stakeholder Impact

• Shareholders: Provides clarity and accuracy regarding the equity compensation details for a key executive, ensuring transparent reporting of insider holdings.

Next Steps

• The stock options will continue to vest in 12 equal monthly installments, with the first installment on October 25, 2025.

Key Dates

Keywords

Clene Inc., CLNN, stock option, Form 4/A, insider transaction, Mark Mortenson, Chief Science Officer, equity compensation